ALNY FY 2022 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.0B+22.9% YoY

Gross Profit

$869M83.7% margin

Operating Income

-$785M-75.7% margin

Net Income

-$1.1B-109.0% margin

EPS (Diluted)

$-9.30

Cash Flow

Operating Cash Flow

-$541M

Free Cash Flow

-$613M

Stock-Based Comp.

$231M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.7B

Stockholders' Equity

-$158M

Cash & Equivalents

$866M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$844M	+22.9%
Gross Profit	$869M	$704M	+23.4%
Operating Income	-$785M	-$709M	-10.8%
Net Income	-$1.1B	-$853M	-32.6%